Last reviewed · How we verify

NCT06203249

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Recruiting now Last updated 12 January 2024
What this trial tests

trial in Microbiome in 50 participants. Currently enrolling.

Timeline
20 January 2024
Primary endpoint
30 December 2025
25 November 2026

Quick facts

Lead sponsorChinese PLA General Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment50
Start date20 January 2024
Primary completion30 December 2025
Estimated completion25 November 2026
Sites1 location across China

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 100, any sex, with Microbiome or Immune Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Correlation between lung microecology and immunity in patients with anti-MDA5 antibody-positive dermatomyositis combined with interstitial lung disease: protocol for a prospective, multicentre cohort study
    Liu S, Duan Z, Wang K, luo G, et al · · 2024 · DOI 10.21203/rs.3.rs-4305936/v1

Verify or expand the search:

Other recruiting trials for Microbiome

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06203249.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing